Precigen Stock Earnings Estimates Increased by HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Precigen to $0.24 from $0.14 and forecast $0.65 EPS for FY2027. The firm maintained its Buy rating and $18 price target; its FY2026 estimate remains below the $0.27 consensus.
• Precigen reported quarterly EPS of $0.08, above the $0.06 consensus, and revenue of $74.15 million, exceeding analysts’ $71.55 million estimate. Revenue rose 2,437.6% year over year.
• Analyst views were generally positive: Citizens JMP raised its price target to $12 and reiterated Market Outperform, while MarketBeat’s average rating was Moderate Buy with a $13.50 average target.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - HC Wainwright boosted their FY2026 earnings per share estimates for Precigen in a note issued to investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.24 per share for the year, up from their previous estimate of $0.14. HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Precigen's current full-year earnings is $0.27 per share. HC Wainwright also issued estimates for Precigen's FY2027 earnings at $0.65 EPS.

Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $74.15 million during the quarter, compared to analysts' expectations of $71.55 million. Precigen had a return on equity of 57.93% and a net margin of 15.55%. The firm's revenue for the quarter was up 2437.6% compared to the same quarter last year. During the same period last year, the firm posted ($1.06) EPS.

PGEN has been the subject of a number of other research reports. Zacks Research downgraded Precigen from a "strong-buy" rating to a "hold" rating in a report on Monday, October 5th. Citizens Jmp upped their price target on shares of Precigen from $11.00 to $12.00 and gave the company a "market outperform" rating in a research note on Thursday. Citigroup reaffirmed a "market outperform" rating on shares of Precigen in a research report on Thursday. Wall Street Zen upgraded shares of Precigen from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Finally, B. Riley Financial began coverage on shares of Precigen in a research note on Friday, September 25th. They issued a "buy" rating and a $12.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $13.50.

Precigen Stock Performance

PGEN opened at $4.47 on Monday. The company has a debt-to-equity ratio of 1.12, a current ratio of 5.58 and a quick ratio of 4.83. The business has a fifty day simple moving average of $6.98 and a 200 day simple moving average of $5.28. Precigen has a 1 year low of $3.04 and a 1 year high of $8.98. The company has a market capitalization of $1.60 billion, a PE ratio of 44.70 and a beta of 1.01.

Hedge Funds Weigh In On Precigen

Hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC raised its stake in Precigen by 5.9% during the third quarter. Commonwealth Equity Services LLC now owns 52,532 shares of the biotechnology company's stock worth $450,000 after acquiring an additional 2,909 shares in the last quarter. Cetera Investment Advisers lifted its holdings in shares of Precigen by 0.9% in the first quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company's stock worth $1,449,000 after acquiring an additional 3,250 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of Precigen by 10.6% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 44,000 shares of the biotechnology company's stock valued at $377,000 after purchasing an additional 4,200 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Precigen by 10.5% in the 2nd quarter. Arizona State Retirement System now owns 53,713 shares of the biotechnology company's stock valued at $306,000 after purchasing an additional 5,086 shares in the last quarter. Finally, Carolina Wealth Advisors LLC bought a new stake in shares of Precigen during the 3rd quarter valued at approximately $46,000. 33.51% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Jeffrey B. Kindler sold 185,000 shares of the business's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total value of $1,376,400.00. Following the completion of the transaction, the director owned 17,100 shares of the company's stock, valued at $127,224. The trade was a 91.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Rutul R. Shah sold 15,342 shares of the business's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total value of $115,065.00. Following the completion of the transaction, the chief operating officer directly owned 468,865 shares of the company's stock, valued at approximately $3,516,487.50. This trade represents a 3.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 235,000 shares of company stock valued at $1,751,400. Corporate insiders own 41.40% of the company's stock.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for Precigen across Q4 2026 and each quarter of 2027, while maintaining a Buy rating and an $18 price target. HC Wainwright estimates and rating
• Positive Sentiment: Citizens JMP raised its price target from $11 to $12 and reiterated a Market Outperform rating, adding to the bullish analyst outlook. Citizens JMP price target
• Positive Sentiment: Precigen’s Q3 revenue of $74.1 million topped the cited FactSet estimate of $71.5 million. The reported $0.08 per-share earnings beat some estimates but fell short of the higher Zacks consensus, making the earnings picture mixed. Q3 revenue results
• Negative Sentiment: A valuation analysis argues that PGEN may already be fully priced based on current earnings, which could limit further upside if future growth does not meet expectations. Precigen valuation analysis

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen's pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.